Full Year 2020 Oxford BioMedica PLC Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Oxford Biomedica's Preliminary Results 2020 Briefing. (Operator Instructions)
I will now hand over to Catherine Isted to open the presentation. Please go ahead.
Good afternoon, ladies and gentlemen. Welcome to Oxford Biomedica's full year results conference call for the year ending the 31st of December 2020. We are delighted today to talk through what hopefully, you will agree, is a very strong set of results. This is a year that the company has thrived in the most uncertain of backdrops and really shown it through highlighting to the world its global leading capabilities. We say we're a lifesaving cell and gene therapy company, and this has never been more true than the year that we've just had.
To discuss the year in more detail, I would like to introduce our presenters on the call today: Our CEO, John Dawson; our CFO, Stuart Paynter; and our Chief Scientific Officer, Kyri Mitrophanous.
With that, I'd
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |